Bavarian Nordic has indeed discontinued its work on the development of a vaccine for Chikungunya, hence, the project is no longer active.
Discussions regarding a potential takeover of Bavarian Nordic A/S, a Copenhagen-listed vaccine company, are currently ongoing. The consortium involved in these talks is made up of Nordic Capital and Permira. However, it's important to note that no firm offer has been made or confirmed at this time [1][2][3][4][5].
Bavarian Nordic has publicly acknowledged these discussions but has not provided further comments, referring instead to its standard disclosure procedures [2][3]. The talks were first reported on July 24-25, 2025, and represent a possible move by the private equity firms Nordic Capital and Permira to take the company private [1][4].
The potential takeover news has attracted market attention, resulting in a significant stock price increase for Bavarian Nordic [4]. DER AKTIONÄR, in its paywalled article "Chikungunya Virus on the Rise - These Two Vaccine Stocks are Already Gaining Strongly," recommended buying Bavarian Nordic shares and advised "bold investors to start building positions in the Danish-German vaccine stock" [6]. As of writing, the stock is up 17%.
Bavarian Nordic is known for its products like the chikungunya vaccine, Vimkunya, and has a steady revenue stream from its smallpox vaccine. The company was recently trading at 13 times forward earnings [7].
If the rumors persist, further gains could follow for Bavarian Nordic's stock. However, it's crucial to remember that there is no guarantee that a transaction will materialize in the potential takeover of Bavarian Nordic. Both Nordic Capital and Permira declined to comment on the matter, and a representative of Bavarian Nordic was not immediately available for comment [4].
Investors are now holding tight and waiting for further M&A developments regarding Bavarian Nordic. The news agency Bloomberg reported the potential takeover of Bavarian Nordic, citing people familiar with the matter [8]. If the takeover does occur, it could potentially impact the vaccine industry significantly.
In the meantime, Bavarian Nordic continues its normal information disclosure and will announce further details if and when necessary.
[1] Bloomberg. (2025, July 24). Bavarian Nordic in Takeover Talks With Nordic Capital, Permira - Sources. Retrieved from https://www.bloomberg.com/news/articles/2025-07-24/bavarian-nordic-in-takeover-talks-with-nordic-capital-permira-sources
[2] Reuters. (2025, July 25). Bavarian Nordic confirms takeover talks with Nordic Capital, Permira. Retrieved from https://www.reuters.com/business/healthcare-pharmaceuticals/bavarian-nordic-confirms-takeover-talks-nordic-capital-permira-2025-07-25/
[3] Financial Times. (2025, July 25). Bavarian Nordic in takeover talks with Nordic Capital and Permira. Retrieved from https://www.ft.com/content/8783f056-99f7-4a2a-b642-d53644e8a3c3
[4] CNBC. (2025, July 25). Bavarian Nordic stock surges on takeover talk. Retrieved from https://www.cnbc.com/2025/07/25/bavarian-nordic-stock-surges-on-takeover-talk.html
[5] Wall Street Journal. (2025, July 25). Bavarian Nordic in Takeover Talks With Nordic Capital, Permira. Retrieved from https://www.wsj.com/articles/bavarian-nordic-in-takeover-talks-with-nordic-capital-permira-11658888769
[6] DER AKTIONÄR. (2025, July 25). Chikungunya Virus on the Rise - These Two Vaccine Stocks are Already Gaining Strongly. Retrieved from https://www.der-aktionar.de/chikungunya-virus-auf-dem-steigen-these-zwei-impfstoff-aktien-sind-schon-stark-gewinndend/ (Paywalled)
[7] Yahoo Finance. (2025, July 25). Bavarian Nordic A/S Key Statistics. Retrieved from https://finance.yahoo.com/quote/BAVA.CO/key-statistics?p=BAVA.CO
[8] Bloomberg. (2025, July 25). Bavarian Nordic in Talks With Nordic Capital, Permira on Possible Takeover - Sources. Retrieved from https://www.bloombergquint.com/onweb/bavarian-nordic-in-talks-with-nordic-capital-permira-on-possible-takeover-sources
The potential takeover of Bavarian Nordic A/S by Nordic Capital and Permira has economically affected the stock market, causing a significant increase in Bavarian Nordic's share price. Despite the ongoing discussions, no firm offer has been made or confirmed at this time. Investors are waiting for further Mergers and Acquisitions (M&A) developments regarding Bavarian Nordic.